Verastem Inc (NASDAQ: VSTM)’s stock price has gone rise by 2.33 in comparison to its previous close of 7.29, however, the company has experienced a 14.24% increase in its stock price over the last five trading days. businesswire.com reported 2025-05-08 that BOSTON–(BUSINESS WIRE)—- $VSTM #FDA–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who received prior systemic therapy. AVMAPKI FAKZYNJA CO-PACK is the fi.
Is It Worth Investing in Verastem Inc (NASDAQ: VSTM) Right Now?
VSTM has 36-month beta value of 0.85. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VSTM is 45.64M, and currently, short sellers hold a 20.43% ratio of that float. The average trading volume of VSTM on May 13, 2025 was 1.05M shares.
VSTM’s Market Performance
The stock of Verastem Inc (VSTM) has seen a 14.24% increase in the past week, with a 60.78% rise in the past month, and a 29.97% gain in the past quarter. The volatility ratio for the week is 11.58%, and the volatility levels for the past 30 days are at 9.86% for VSTM. The simple moving average for the past 20 days is 9.48% for VSTM’s stock, with a 61.53% simple moving average for the past 200 days.
Analysts’ Opinion of VSTM
Many brokerage firms have already submitted their reports for VSTM stocks, with Jefferies repeating the rating for VSTM by listing it as a “Buy.” The predicted price for VSTM in the upcoming period, according to Jefferies is $15 based on the research report published on April 10, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see VSTM reach a price target of $10, previously predicting the price at $7. The rating they have provided for VSTM stocks is “Buy” according to the report published on March 24th, 2025.
BTIG Research gave a rating of “Buy” to VSTM, setting the target price at $20 in the report published on December 31st of the previous year.
VSTM Trading at 15.56% from the 50-Day Moving Average
After a stumble in the market that brought VSTM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.82% of loss for the given period.
Volatility was left at 9.86%, however, over the last 30 days, the volatility rate increased by 11.58%, as shares surge +57.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +35.56% upper at present.
During the last 5 trading sessions, VSTM rose by +15.01%, which changed the moving average for the period of 200-days by +152.86% in comparison to the 20-day moving average, which settled at $6.82. In addition, Verastem Inc saw 44.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VSTM starting from Paterson Dan, who sale 820 shares at the price of $7.30 back on May 05 ’25. After this action, Paterson Dan now owns 345,659 shares of Verastem Inc, valued at $5,986 using the latest closing price.
Calkins Daniel, the Chief Financial Officer of Verastem Inc, sale 65 shares at $6.89 during a trade that took place back on Mar 20 ’25, which means that Calkins Daniel is holding 86,374 shares at $448 based on the most recent closing price.
Stock Fundamentals for VSTM
Current profitability levels for the company are sitting at:
- -11.5 for the present operating margin
- 1.0 for the gross margin
The net margin for Verastem Inc stands at -13.06. The total capital return value is set at -1.63. Equity return is now at value -526.33, with -103.99 for asset returns.
Based on Verastem Inc (VSTM), the company’s capital structure generated 3.16 points at debt to capital in total, while cash flow to debt ratio is standing at -2.48. The debt to equity ratio resting at -1.46. The interest coverage ratio of the stock is -25.2.
Currently, EBITDA for the company is -125.86 million with net debt to EBITDA at 0.33. When we switch over and look at the enterprise to sales, we see a ratio of 33.78. The receivables turnover for the company is 50.0for trailing twelve months and the total asset turnover is 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.07.
Conclusion
To put it simply, Verastem Inc (VSTM) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
